CDMO Expansion ProBioGen is a growing contract development and manufacturing organization with multiple Berlin-based manufacturing lines and a 30+ year track record, signaling capacity and reliability for partnered biopharma programs, including proteins, antibodies, viral vectors, and vaccines.

GMP Vaccine Capabilities Recent news highlights GMP-compliant development and production of vaccine-related assets, including Bundibugyo-specific and recombinant MVA drug substances, presenting opportunities to engage on early development, scale-up, and late-stage manufacturing for viral/vector vaccines.

CMC Navigator The launch of CMC Navigator offering defined chemistry, manufacturing, and controls service models creates a structured, sale-ready pathway for clients needing end-to-end CDMO support, reducing engagement risk and accelerating project timelines.

Strategic Partnerships Active collaborations with external entities such as VarmX for Factor X development position ProBioGen as a partner of choice for specialized biotherapeutics, opening doors for co-development, clinical manufacturing, and early-access programs.

R&D Innovation New capabilities such as avian designer cell lines for poxvirus vaccine development indicate a focus on innovative platforms and faster timelines, appealing to biotech companies pursuing next-generation vaccines and complex biologics.